The Cardiac Safety of Chloroquine Phosphate Treatment in Patients with Systemic Lupus Erythematosus: The Influence on Arrhythmia, Heart Rate Variability and Repolarization Parameters
Identifieur interne : 001C51 ( Main/Exploration ); précédent : 001C50; suivant : 001C52The Cardiac Safety of Chloroquine Phosphate Treatment in Patients with Systemic Lupus Erythematosus: The Influence on Arrhythmia, Heart Rate Variability and Repolarization Parameters
Auteurs : A. Wozniacka [Pologne] ; I. Cygankiewicz [Pologne] ; M. Chudzik [Pologne] ; A. Sysa-J Drzejowska ; Jk Wranicz [Pologne]Source :
- Lupus [ 0961-2033 ] ; 2006-08.
English descriptors
- Teeft :
- Acta derm venereol, Antimalarial, Antimalarial drugs, Arrhythmia, Arrhythmic events, Arthritis rheum, Cardiac, Cardiac damage, Cardiac safety, Cardiac toxicity, Cardiovascular toxicity, Chloroquine, Chloroquine administration, Chloroquine phosphate, Chloroquine phosphate treatment, Chloroquine treatment, Complete heart block, Conduction, Conduction disorders, Conduction disturbances, Daily dose, Disease activity, Entire recording, Erythematosus, Frequency domain, Frequency power, Gastrointestinal reactions, Heart rate, Heart rate variability, Holter, Holter monitoring, Immune activation, Last decade, Long term treatment, Lupus, Lupus patients, Medical university, Other hand, Oxford medilog, Paroxysmal arrhythmias, Rare complication, Repolarization, Repolarization parameters, Side effects, Sinus rhythm, Systemic, Systemic lupus erythematosus, Toxicity.
Abstract
Antimalarials are used to treat cutaneous and systemic lupus erythematosus (SLE). Even though cardiac damage is a rare complication, over the last decade several reports have raised the issue of cardiotoxicity associated with antimalarials. Therefore, the aim of study was to evaluate the influence of seven-month chloroquine treatment with a 250 mg daily dose on arrhythmia, conduction disturbances as well as heart rate variability and repolarization parameters assessed in 24-hour Holter monitoring. The studied group included 28 SLE patients treated with chloroquine as a monotherapy. In all the patients standard 12 leads surface ECG (50 mm) and the 24-hour ECG Holter monitoring (Oxford Medilog Excel-2) were performed before and after chloroquine phosphate treatment. All subjects presented sinus rhythm both at the enrollment and after treatment. No episodes of paroxysmal arrhythmias or conduction disturbances were reported during the study. All the patients were characterized by tendency to tachycardia, but no significant differences in mean heart rate were found before and after chloroquine administration. Similarly, no changes in heart rate variability or repolarization parameters were observed.
Url:
DOI: 10.1191/0961203306lu2345oa
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000007
- to stream Istex, to step Curation: 000007
- to stream Istex, to step Checkpoint: 000B19
- to stream Main, to step Merge: 001C63
- to stream Main, to step Curation: 001C51
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The Cardiac Safety of Chloroquine Phosphate Treatment in Patients with Systemic Lupus Erythematosus: The Influence on Arrhythmia, Heart Rate Variability and Repolarization Parameters</title><author wicri:is="90%"><name sortKey="Wozniacka, A" sort="Wozniacka, A" uniqKey="Wozniacka A" first="A" last="Wozniacka">A. Wozniacka</name></author><author wicri:is="90%"><name sortKey="Cygankiewicz, I" sort="Cygankiewicz, I" uniqKey="Cygankiewicz I" first="I" last="Cygankiewicz">I. Cygankiewicz</name></author><author wicri:is="90%"><name sortKey="Chudzik, M" sort="Chudzik, M" uniqKey="Chudzik M" first="M" last="Chudzik">M. Chudzik</name></author><author wicri:is="90%"><name sortKey="Sysa J Drzejowska, A" sort="Sysa J Drzejowska, A" uniqKey="Sysa J Drzejowska A" first="A" last="Sysa-J Drzejowska">A. Sysa-J Drzejowska</name></author><author wicri:is="90%"><name sortKey="Wranicz, Jk" sort="Wranicz, Jk" uniqKey="Wranicz J" first="Jk" last="Wranicz">Jk Wranicz</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:7ECB3725C0AFEA1A0C67507FC3E8DED40F5500A1</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1191/0961203306lu2345oa</idno><idno type="url">https://api.istex.fr/ark:/67375/M70-GC0VD9XR-3/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000007</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000007</idno><idno type="wicri:Area/Istex/Curation">000007</idno><idno type="wicri:Area/Istex/Checkpoint">000B19</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000B19</idno><idno type="wicri:doubleKey">0961-2033:2006:Wozniacka A:the:cardiac:safety</idno><idno type="wicri:Area/Main/Merge">001C63</idno><idno type="wicri:Area/Main/Curation">001C51</idno><idno type="wicri:Area/Main/Exploration">001C51</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The Cardiac Safety of Chloroquine Phosphate Treatment in Patients with Systemic Lupus Erythematosus: The Influence on Arrhythmia, Heart Rate Variability and Repolarization Parameters</title><author wicri:is="90%"><name sortKey="Wozniacka, A" sort="Wozniacka, A" uniqKey="Wozniacka A" first="A" last="Wozniacka">A. Wozniacka</name><affiliation></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Pologne</country></affiliation></author><author wicri:is="90%"><name sortKey="Cygankiewicz, I" sort="Cygankiewicz, I" uniqKey="Cygankiewicz I" first="I" last="Cygankiewicz">I. Cygankiewicz</name><affiliation wicri:level="1"><country xml:lang="fr">Pologne</country><wicri:regionArea>Department of Cardiology, Medical University of Lodz</wicri:regionArea><wicri:noRegion>Medical University of Lodz</wicri:noRegion></affiliation></author><author wicri:is="90%"><name sortKey="Chudzik, M" sort="Chudzik, M" uniqKey="Chudzik M" first="M" last="Chudzik">M. Chudzik</name><affiliation wicri:level="1"><country xml:lang="fr">Pologne</country><wicri:regionArea>Department of Cardiology, Medical University of Lodz</wicri:regionArea><wicri:noRegion>Medical University of Lodz</wicri:noRegion></affiliation></author><author wicri:is="90%"><name sortKey="Sysa J Drzejowska, A" sort="Sysa J Drzejowska, A" uniqKey="Sysa J Drzejowska A" first="A" last="Sysa-J Drzejowska">A. Sysa-J Drzejowska</name><affiliation><wicri:noCountry code="no comma">Department of Dermatology</wicri:noCountry></affiliation></author><author wicri:is="90%"><name sortKey="Wranicz, Jk" sort="Wranicz, Jk" uniqKey="Wranicz J" first="Jk" last="Wranicz">Jk Wranicz</name><affiliation wicri:level="1"><country xml:lang="fr">Pologne</country><wicri:regionArea>Department of Cardiology, Medical University of Lodz</wicri:regionArea><wicri:noRegion>Medical University of Lodz</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Lupus</title><idno type="ISSN">0961-2033</idno><idno type="eISSN">1477-0962</idno><imprint><publisher>Sage Publications</publisher><pubPlace>Sage CA: Thousand Oaks, CA</pubPlace><date type="published" when="2006-08">2006-08</date><biblScope unit="volume">15</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="521">521</biblScope><biblScope unit="page" to="525">525</biblScope></imprint><idno type="ISSN">0961-2033</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0961-2033</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Acta derm venereol</term><term>Antimalarial</term><term>Antimalarial drugs</term><term>Arrhythmia</term><term>Arrhythmic events</term><term>Arthritis rheum</term><term>Cardiac</term><term>Cardiac damage</term><term>Cardiac safety</term><term>Cardiac toxicity</term><term>Cardiovascular toxicity</term><term>Chloroquine</term><term>Chloroquine administration</term><term>Chloroquine phosphate</term><term>Chloroquine phosphate treatment</term><term>Chloroquine treatment</term><term>Complete heart block</term><term>Conduction</term><term>Conduction disorders</term><term>Conduction disturbances</term><term>Daily dose</term><term>Disease activity</term><term>Entire recording</term><term>Erythematosus</term><term>Frequency domain</term><term>Frequency power</term><term>Gastrointestinal reactions</term><term>Heart rate</term><term>Heart rate variability</term><term>Holter</term><term>Holter monitoring</term><term>Immune activation</term><term>Last decade</term><term>Long term treatment</term><term>Lupus</term><term>Lupus patients</term><term>Medical university</term><term>Other hand</term><term>Oxford medilog</term><term>Paroxysmal arrhythmias</term><term>Rare complication</term><term>Repolarization</term><term>Repolarization parameters</term><term>Side effects</term><term>Sinus rhythm</term><term>Systemic</term><term>Systemic lupus erythematosus</term><term>Toxicity</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Antimalarials are used to treat cutaneous and systemic lupus erythematosus (SLE). Even though cardiac damage is a rare complication, over the last decade several reports have raised the issue of cardiotoxicity associated with antimalarials. Therefore, the aim of study was to evaluate the influence of seven-month chloroquine treatment with a 250 mg daily dose on arrhythmia, conduction disturbances as well as heart rate variability and repolarization parameters assessed in 24-hour Holter monitoring. The studied group included 28 SLE patients treated with chloroquine as a monotherapy. In all the patients standard 12 leads surface ECG (50 mm) and the 24-hour ECG Holter monitoring (Oxford Medilog Excel-2) were performed before and after chloroquine phosphate treatment. All subjects presented sinus rhythm both at the enrollment and after treatment. No episodes of paroxysmal arrhythmias or conduction disturbances were reported during the study. All the patients were characterized by tendency to tachycardia, but no significant differences in mean heart rate were found before and after chloroquine administration. Similarly, no changes in heart rate variability or repolarization parameters were observed.</div></front></TEI><affiliations><list><country><li>Pologne</li></country></list><tree><noCountry><name sortKey="Sysa J Drzejowska, A" sort="Sysa J Drzejowska, A" uniqKey="Sysa J Drzejowska A" first="A" last="Sysa-J Drzejowska">A. Sysa-J Drzejowska</name></noCountry><country name="Pologne"><noRegion><name sortKey="Wozniacka, A" sort="Wozniacka, A" uniqKey="Wozniacka A" first="A" last="Wozniacka">A. Wozniacka</name></noRegion><name sortKey="Chudzik, M" sort="Chudzik, M" uniqKey="Chudzik M" first="M" last="Chudzik">M. Chudzik</name><name sortKey="Cygankiewicz, I" sort="Cygankiewicz, I" uniqKey="Cygankiewicz I" first="I" last="Cygankiewicz">I. Cygankiewicz</name><name sortKey="Wranicz, Jk" sort="Wranicz, Jk" uniqKey="Wranicz J" first="Jk" last="Wranicz">Jk Wranicz</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C51 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001C51 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:7ECB3725C0AFEA1A0C67507FC3E8DED40F5500A1
|texte= The Cardiac Safety of Chloroquine Phosphate Treatment in Patients with Systemic Lupus Erythematosus: The Influence on Arrhythmia, Heart Rate Variability and Repolarization Parameters
}}
| This area was generated with Dilib version V0.6.33. |  |